An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss. Over the last four quarters, the company has beaten consensus EPS cash credit vs overdraft estimates four times. For Kenvue, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company’s earnings prospects. Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate.

J&J de­buts Ken­vue as new name for $15B con­sumer health busi­ness spin­off

These non-GAAP financial measures are not prepared in accordance with U.S. In addition, other companies may use similarly titled non-GAAP financial measures that are calculated differently from the way the Company calculates such measures. Accordingly, the non-GAAP financial measures may not be comparable to such similarly titled non-GAAP financial measures used by other companies. The Company cautions you not to place undue reliance on these non-GAAP financial measures, but instead to consider them with the most directly comparable U.S.

Meet the Kenvue product tester who has worked with our brands for 20 years

First quarter Net sales increased 1.1% on top of a 7.3% increase in the prior year period. Organic growth1 was 1.9% on top of 11.2% Organic growth in the prior year period. Increases in Net sales and Organic growth were primarily driven by sustained momentum in Self Care on strong consumer demand and growth in Essential Health led by Oral Care, partially offset by underperformance in Skin Health and Beauty. Citigroup dropped their price target on Kenvue from $21.00 to $20.00 and set a “neutral” rating for the company in a research report on Wednesday, July 10th.

Kenvue innovations: 2 new products help with pain relief, facial cleansing

While Kenvue currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. For the last reported quarter, it was expected that Kenvue would post earnings of $0.25 per share when it actually produced earnings of $0.28, delivering a surprise of +12%. The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate.

1. Our team members share a digital-first mindset, with an approach to innovation grounded in deep human insights and work every day to earn a place for our products in consumers’ hearts and homes.
2. For full year 2024, Kenvue continues to expect an Effective tax rate between 26.5% to 27.5%, and an Adjusted effective tax rate between 25.5% to 26.5%.
3. Upon joining the Board, Ms. Pawlus will serve as a member of the Audit Committee.
4. Kenvue continues to expect full year 2024 Adjusted operating income margin to be slightly below 2023 as strong gross margin progression is offset by the impact of absorbing a full year of public company costs and approximately 50 basis points of foreign currency headwinds.

This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return.

things you might not know about the most-trusted brand in the U.S.*

It isn’t an attractive option for growth investors, and while the dividend could be relatively high out of the gate, the risk the company faces with respect to talc liabilities negates those positives for me. Investors who are interested in owning the stock may want to see how the company does in its first few quarters before buying shares of the business to see how it performs, as there’s certainly no rush to buy it now. KVUE would be worth just $18/share today – a 16% downside to the midpoint IPO price range.

Our community is about connecting people through open and thoughtful conversations. We want our readers to share their views and exchange ideas and facts in a safe space. In other words, this IPO will take investors’ money while giving them almost https://www.1investing.in/ no voting power or control of corporate governance. I present an additional DCF scenario to highlight the downside potential in the stock should Kenvue grow sales at management’s expectation, which is lower than third-party estimates.

Our team members share a digital-first mindset, with an approach to innovation grounded in deep human insights and work every day to earn a place for our products in consumers’ hearts and homes. At Kenvue, we believe everyday care can not only make people well; it can make them whole. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand Adhesive Bandages, Johnson’s®, Listerine®, Neutrogena®, and Tylenol®, are science-backed and recommended by healthcare professionals around the world. In May 2023, Kenvue made our debut as a public company on the New York Stock Exchange, trading under the KVUE ticker symbol. Today, Kenvue is the world’s largest pure-play consumer health company by revenue, with annual sales of ~$15 billion in 2022.

Cautions Concerning Forward-Looking StatementsThis press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, changes to the Board of Directors. Forward-looking statements may be identified by the use of words such as “plans,” “expects,” “will,” “anticipates,” “estimates” and other words of similar meaning. Readers are cautioned not to rely on these forward-looking statements, which are based on current expectations of future events. Kenvue and its affiliates undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or developments or otherwise.

The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. The consensus EPS estimate for the quarter has been revised 1.04% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period. The earnings report, which is expected to be released on August 6, 2024, might help the stock move higher if these key numbers are better than expectations.

Kenvue continues to expect full year 2024 Adjusted diluted earnings per share to be in the range of $1.10 – $1.20. Our Healthy Lives Mission — our environmental, social and governance strategy — strives to nurture healthy people, enrich a healthy planet and maintain healthy practice. Within our three Healthy Lives Mission pillars, we are focused on nine priority topics and have set goals and commitments to hold us accountable and help drive the positive impact we aim to create. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it’s worth taking a look at the surprise history for gauging its influence on the upcoming number. A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

(1) Includes the provision for taxes and minority interest expense related to Deferred Markets recognized within Other operating expense (income), net, which are payable to Johnson & Johnson through interim agreements until these Deferred Markets can be transferred to the Company. Jurisdictions in which the transfer from Johnson & Johnson of certain assets and liabilities were deferred in order to ensure compliance with applicable law, to obtain necessary governmental approvals and other consents, and for other business reasons. MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on…